Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmicals宣布将提供该公司正在德国柏林进行的帕拉西司朗与Cdk4/6抑制剂Ribociclib联合使用的1b/2期临床研究的新临床数据
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmicals宣布将提供该公司正在德国柏林进行的帕拉西司朗与Cdk4/6抑制剂Ribociclib联合使用的1b/2期临床研究的新临床数据